IFRS 2®, Share-based Payment, applies when a company acquires or receives goods and services in exchange for an equity-based payment. These goods can include inventories, property, plant and equipment, intangible assets, and other non-financial assets. Services can include that provided by employees in exchange for an equity-based payment eg share options. There are two notable exceptions: shares issued in a business combination, which are dealt with under IFRS 3®, Business Combinations; and contracts for the purchase of goods that are within the scope of IAS 32® and IAS 39®. In addition, a purchase of treasury shares would not fall within the scope of IFRS 2, nor would a rights issue where some of the employees are shareholders.
Examples of some of the arrangements that would be accounted for under IFRS 2 include call options, share appreciation rights, share ownership schemes, and payments for services made to external consultants based on the company’s equity capital.
This article will cover:
IFRS 2 requires an expense to be recognised for the goods or services received by a company. The corresponding entry in the accounting records will either be a liability or an increase in the equity of the company, depending on whether the transaction is to be settled in cash or in equity shares. Goods or services acquired in a share-based payment transaction should be recognised when they are received. In the case of goods, this is obviously the date when this occurs. However, it is often more difficult to determine when services are received. If shares are issued that vest immediately, then it can be assumed that these are in consideration of past services. As a result, the expense should be recognised immediately.
Alternatively, if the share-based payment vest (becomes an entitlement) in the future, then it is assumed that the equity instruments relate to future services and recognition is therefore spread over that vesting period (period during which specified conditions are to be satisfied eg remain in employment for 3 years).
Equity-settled transactions with employees and directors would normally be expensed and would be based on their fair value at the grant date (date at which the entity and other party agree to a share-based transaction). Fair value should be based on market price wherever this is possible. Many shares and share options will not be traded on an active market. If this is the case then valuation techniques, such as the option pricing model, would be used. IFRS 2 does not set out which pricing model should be used, but describes the factors that should be taken into account. It says that ‘intrinsic value’ should only be used where the fair value cannot be reliably estimated. Intrinsic value is the difference between the fair value of the shares and the price that is to be paid for the shares by the counterparty.
The objective of IFRS 2 is to determine and recognise the compensation costs over the period in which the services are rendered. For example, if a company grants share options to employees that vest in the future only if they are still employed at the end of the vesting period, then the accounting process is as follows:
EXAMPLE 1
A company issued share options on 1 June 20X6 to pay for the purchase of inventory. The inventory is eventually sold on 31 December 20X8. The value of the inventory on 1 June 20X6 was $6m and this value was unchanged up to the date of sale. The sale proceeds were $8m. The shares issued have a market value of $6.3m.
How will this purchase of inventory be dealt with in the financial statements?
Answer
IFRS 2 states that the fair value of the goods and services received should be used to value the share options unless the fair value of the goods cannot be measured reliably. Thus equity would be increased by $6m and inventory increased by $6m. The inventory value will be expensed on sale.
Schemes often contain conditions which must be met before there is entitlement to the shares. These are called vesting conditions. If the conditions are specifically related to the market price of the company’s shares then such conditions are ignored for the purposes of estimating the number of equity shares that will vest. The thinking behind this is that these conditions have already been taken into account when fair valuing the shares. If the vesting or performance conditions are based on, for example, the growth in profit or earnings per share, then it will have to be taken into account in estimating the fair value of the option at the grant date.
EXAMPLE 2
A company grants 2,000 share options to each of its three directors on 1 January 20X6, subject to the directors being employed on 31 December 20X8. The options vest on 31 December 20X8. The fair value of each option on 1 January 20X6 is $10, and it is anticipated that on 1 January 20X6 all of the share options will vest on 31 December 20X8. The options will only vest if the company’s share price reaches $14 per share.
The share price at 31 December 20X6 is $8 and it is not anticipated that it will rise over the next two years. It is anticipated that on 31 December 20X6 only two directors will be employed on 31 December 20X8.
How will the share options be treated in the financial statements for the year ended 31 December 20X6?
Answer
The market-based condition (ie the increase in the share price) can be ignored for the purpose of the calculation. However the employment condition (it is a vesting condition) must be taken into account. The options will be treated as follows:
2,000 options x 2 directors x $10 x 1 year / 3 years = $13,333
Equity will be increased by this amount and an expense shown in profit or loss for the year ended 31 December 20X6. Note only 2 directors are used in the calculation as this is the estimate of those who will actually qualify for the share options. The expense is spread over the vesting period (1 January 20X6 to 31 December 20X8).
Cash-settled share-based payment transactions occur where goods or services are paid for at amounts that are based on the price of the company’s equity instruments. The expense for cash settled transactions is the cash paid by the company.
As an example, share appreciation rights entitle employees to cash payments equal to the increase in the share price of a given number of the company’s shares over a given period. This creates a liability, and the recognised cost is based on the fair value of the instrument at the reporting date. The fair value of the liability is re-measured at each reporting date until settlement.
EXAMPLE 3
Jay, a public limited company, has granted 300 share appreciation rights to each of its 500 employees on 1 August 20X5. The management feel that as at 31 July 20X6, the year end of Jay, 80% of the awards will vest on 31 July 20X7. The fair value of each share appreciation right on 31 July 20X6 is $15.
What is the fair value of the liability to be recorded in the financial statements for the year ended 31 July 20X6?
Answer
300 rights x 500 employees x 80% x $15 x 1 year / 2 years = $900,000
In some jurisdictions, a tax allowance is often available for share-based transactions. It is unlikely that the amount of tax deducted will equal the amount charged to profit or loss under IFRS 2. Often, the tax deduction is based on the option’s intrinsic value, which is the difference between the fair value and exercise price of the share. A deferred tax asset will therefore arise which represents the difference between a tax base of the employee’s services received to date and the carrying amount, which will effectively normally be zero. A deferred tax asset will be recognised if the company has sufficient future taxable profits against which it can be offset.
For cash settled share-based payment transactions, the standard requires the estimated tax deduction to be based on the current share price. As a result, all tax benefits received (or expected to be received) are recognised in the profit or loss.
EXAMPLE 4
A company operates in a country where it receives a tax deduction equal to the intrinsic value of the share options at the exercise date. The company grants share options to its employees on 1 January 20X5 with a fair value of $4.8m at the grant date. The intrinsic value of the options at 31 December 20X5 is $3.8m and at the exercise dateis $4.2m. The tax rate applicable to the company is 30% and the share options vest on 31 December 20X6.
What deferred tax asset should be recorded in the financial statements for the year ended 31 December 20X5 and 20X6?
Answer
A deferred tax asset would be recognised of:
At 31 December 20X5
$3.8m @ 30% tax rate x 1 year / 2 years = $570,000
At 31 December 20X6
$4.2m @ 30% tax rate = $1,260,000
On exercise the deferred tax asset becomes a current tax asset.
The deferred tax will only be recognised if there are sufficient future taxable profits available.
IFRS 2 requires extensive disclosures under three main headings:
The standard is applicable to equity instruments granted after 7 November 2002 but not yet vested on the effective date of the standard, which is 1 January 2005. IFRS 2 applies to liabilities arising from cash-settled transactions that existed at 1 January 2005.
Practice questions
| $ |
|
---|---|---|
1 January 20X6 | 15 |
|
31 December 20X6 | 18 |
|
31 December 20X7 | 20 |
|
What will be recorded in the financial statements on 31 December 20X6 for the share appreciation rights?
Answers
Written by a member of the DipIFR examining team